Abeona Therapeutics (NASDAQ:ABEO) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Abeona Therapeutics (NASDAQ:ABEO) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.01, FiscalAI reports. The firm had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $5.65 million.

Here are the key takeaways from Abeona Therapeutics’ conference call:

• Company launched ZEVASKYN (approved April 2025) and treated its first commercial patients in December 2025, reporting growing patient interest—identified eligible patients have risen from ~50 to more than 100 after field-team outreach.
• Reimbursement environment is favorable: major commercial payers cover ZEVASKYN (about 80% of commercially covered lives), Medicaid baseline coverage in all 50 states, and a permanent HCPCS J-code effective Jan 1, 2026, which should streamline billing and access.
• Manufacturing is operating at ~6 patients/month with a planned ramp to ~10/month in H2 2026 and management says the prior sterility assay issue has been resolved, though they note empirical proof will accumulate only as runs continue.
• Commercial rollout pace is variable and constrained by multi-month QTC onboarding and administrative steps (typical patient journey ~4–5 months including ~25 days manufacturing); management flagged that ~3–3.5 treated patients per month are needed to reach company-level profitability, making near-term execution a key risk.
• 2025 results were bolstered by the sale of a rare pediatric disease priority review voucher, generating a $152.4 million gain; year-end cash and short-term investments totaled $191.4 million, providing runway to support the commercial ramp.

Abeona Therapeutics Trading Down 3.8%

Shares of ABEO stock opened at $4.76 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.74 and a quick ratio of 9.53. The firm has a market cap of $257.94 million, a PE ratio of 3.87 and a beta of 1.13. The company has a 50-day moving average of $5.11 and a two-hundred day moving average of $5.23. Abeona Therapeutics has a 1-year low of $3.93 and a 1-year high of $7.54.

Insiders Place Their Bets

In related news, Director Christine Berni Silverstein sold 20,070 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $5.09, for a total transaction of $102,156.30. Following the transaction, the director owned 137,722 shares of the company’s stock, valued at approximately $701,004.98. This represents a 12.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leila Alland sold 18,065 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $5.09, for a total value of $91,950.85. Following the transaction, the director owned 173,614 shares of the company’s stock, valued at $883,695.26. This trade represents a 9.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 209,605 shares of company stock worth $1,101,300. Insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ABEO. Goldman Sachs Group Inc. increased its holdings in Abeona Therapeutics by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock valued at $954,000 after buying an additional 66,422 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Abeona Therapeutics by 129.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after buying an additional 623,243 shares during the last quarter. Creative Planning lifted its holdings in Abeona Therapeutics by 43.0% during the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 4,305 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Abeona Therapeutics by 255.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock worth $4,721,000 after acquiring an additional 597,373 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth about $27,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on ABEO shares. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, March 10th. Oppenheimer reaffirmed an “outperform” rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. Stifel Nicolaus set a $17.00 price objective on Abeona Therapeutics in a report on Tuesday. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Abeona Therapeutics has an average rating of “Moderate Buy” and an average price target of $19.00.

Key Abeona Therapeutics News

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: Commercial progress — Abeona completed its first commercial ZEVASKYN® patient treatment in December and says launch momentum is building into 1Q26; management is prioritizing steady biopsy/treatment cadence. Abeona Therapeutics Reports Full Year 2025 Financial Results and Corporate Updates
• Positive Sentiment: Commercial demand signals — Management and call highlights point to strong/ doubling patient demand for ZEVASKYN and plans to activate seven qualified treatment centers (QTCs) by end-2026 to scale treatments. Q4 2025 Earnings Call Highlights Abeona targets activation of 7 QTCs
• Positive Sentiment: Strong balance sheet — Abeona reported approximately $191.4M in cash, equivalents and short-term investments as of Dec. 31, 2025, giving the company runway to fund commercialization and operations. Full Year 2025 Financial Results
• Neutral Sentiment: Investor materials available — The full earnings call transcript and press release are posted for detailed review of guidance, commercialization cadence, and clinic activation plans. Earnings Call Transcript
• Neutral Sentiment: Short interest reporting appears anomalous (entries show 0 shares / NaN increases); current short-interest data is not providing a clear market signal.
• Negative Sentiment: Earnings miss — Q4 EPS of ($0.34) missed consensus by $0.01 and revenue came in at $3.0M vs. $5.65M expected, a sizable top-line shortfall that likely pressured the stock today. Q4 2025 Earnings / Financial Results

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.